Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iradimed (IRMD) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Iradimed (IRMD) over the last 13 years, with Q3 2025 value amounting to $5.6 million.

  • Iradimed's Net Income towards Common Stockholders rose 1043.99% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.5 million, marking a year-over-year increase of 1907.69%. This contributed to the annual value of $18.5 million for FY2024, which is 1753.58% up from last year.
  • Latest data reveals that Iradimed reported Net Income towards Common Stockholders of $5.6 million as of Q3 2025, which was up 1043.99% from $5.8 million recorded in Q2 2025.
  • Iradimed's Net Income towards Common Stockholders' 5-year high stood at $5.8 million during Q2 2025, with a 5-year trough of $1.4 million in Q1 2021.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was $3.9 million (2021), whereas its average is $3.8 million.
  • Data for Iradimed's Net Income towards Common Stockholders shows a peak YoY increase of 27919.82% (in 2021) and a maximum YoY decrease of 2161.2% (in 2021) over the last 5 years.
  • Iradimed's Net Income towards Common Stockholders (Quarter) stood at $3.9 million in 2021, then fell by 5.63% to $3.7 million in 2022, then fell by 15.13% to $3.1 million in 2023, then soared by 42.7% to $4.4 million in 2024, then rose by 25.34% to $5.6 million in 2025.
  • Its Net Income towards Common Stockholders stands at $5.6 million for Q3 2025, versus $5.8 million for Q2 2025 and $4.7 million for Q1 2025.